Newest FDA-approved opioid use disorder drug enters the market with flexible dosing
The newest approved opioid use disorder drug is leaning on its flexible dosing schedule and injection site convenience to gain traction. Braeburn’s Brixadi can be administered as a weekly dose, but also as a monthly dose like its competitors. It also counts the drug’s lack of refrigeration needed and ability for injections at multiple sites on the body as additional differentiators.
“A weekly dose is important in this category in particular because clinicians like to see patients on a frequent basis especially early in the diagnosis or upon relapse,” Braeburn president and CEO Mike Derkacz said.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
